🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06990295
Recruiting Not applicable

Focused Ultrasound Spleen Stimulation and Inflammation in Septic Shock

NCT06990295 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Wannan Medical College
Phase
Not applicable
Started
2025-07-25
Last updated
2026-05-19

Condition(s) studied

Septic ShockInflammatory CytokinesSpleen NeuromodulationFocused UltrasoundCritical Care

Investigational drug(s) / intervention(s)

Focused Ultrasound Spleen Neuromodulation

Focused Ultrasound Spleen Neuromodulation: A portable focused ultrasound device is used to stimulate the spleen area under real-time imaging guidance. Each session lasts approximately 20 minutes, repeated twice daily for five days.

Study summary

This study evaluates the safety and effectiveness of focused ultrasound spleen neuromodulation in patients with septic shock, a life-threatening condition characterized by excessive inflammation and organ dysfunction. The primary objective is to determine whether non-invasive, focused ultrasound stimulation of the spleen can reduce circulating inflammatory cytokine levels in this patient population.

Eligibility Criteria:

Adults aged 18 years or older Diagnosed with septic shock and admitted to the ICU within 24 hours Expected to require intensive care for at least 72 hours

Study Protocol:

Participants will be randomly assigned to one of two groups:

Intervention Group: Will receive standard septic shock care plus twice-daily focused ultrasound stimulation over the spleen for five days, using a portable device.

Control Group: Will receive standard septic shock care alone. Blood samples will be collected at baseline and Day 5 to measure inflammatory cytokine levels, including TNF-α, IL-1β, IL-6, and IL-10. Additional assessments will include lymphocyte subpopulations, organ function scores, ICU length of stay, 28-day mortality, and adverse events.

Outcome Measures:

Primary: Change in levels of inflammatory cytokines on Day 5. Secondary: Changes in organ function (SOFA score), ICU length of stay, 28-day survival, and safety/tolerability of the intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years, regardless of sex * Diagnosed with septic shock according to Sepsis-3 criteria: Sequential Organ Failure Assessment (SOFA) score ≥ 2 and requiring vasopressor support to maintain a mean arterial pressure (MAP) ≥ 65 mmHg. * Admitted to the ICU within 24 hours of septic shock diagnosis * Expected to require intensive care for at least 72 hours * Informed consent obtained from the patient or legal representative Exclusion Criteria: * Known pregnancy or breastfeeding * Participation in another interventional clinical trial within 30 days * Known immunodeficiency or ongoing immunosuppressive therapy * Malignancy with life expectancy \< 6 months * Contraindications to focused ultrasound (e.g., splenic trauma, splenectomy, local skin infection) * Do-not-resuscitate (DNR) order or expected death within 24 hours * Any other condition deemed unsuitable for participation by the investigators

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College) Wuhu Anhui Recruiting

More First Affiliated Hospital of Wannan Medical College trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06990295 on ClinicalTrials.gov ↗ ← All trials in China